Trials / Completed
CompletedNCT05861375
Liver Biomarkers in Anorexia Nervosa
Assessment of Liver Damage Using the Fibroscan in Patients With Anorexia Nervosa
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 43 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.
Detailed description
Prevalence of hepatic fibrosis will be non-invasively investigated, in the Anorexia Nervosa inpatient population, using the Fibroscan ®. Furthermore, liver blood markers will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Fibroscan | Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed. |
Timeline
- Start date
- 2023-06-23
- Primary completion
- 2025-06-27
- Completion
- 2025-06-27
- First posted
- 2023-05-16
- Last updated
- 2026-04-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05861375. Inclusion in this directory is not an endorsement.